Population Pharmacodynamics and Pharmacokinetics of Remifentanil as a Supplement to Nitrous Oxide Anesthesia for Elective Abdominal Surgery
Authors:
- David R. DroverDDDavid R. Drover
- Harry J. M. LemmensHLHarry J. M. Lemmens
- 1 October 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 89 (4) , 869-877
Abstract
Background: Remifentanil blood concentrations necessary for adequate intraoperative anesthesia have not been defined. The goal of this study was to determine the blood concentrations of remifentanil needed for anesthesia with 66% nitrous oxide during intraabdominal surgery. In addition, the pharmacokinetics of remifentanil and the effects of covariates on both the pharmacodynamics and the pharmacokinetics were determined. Methods: Anesthesia was induced and maintained with 66% nitrous oxide in oxygen and remifentanil. Remifentanil was administered by a computer-controlled infusion pump that rapidly attained, and then maintained, constant remifentanil blood concentrations. If the patient showed signs of inadequate anesthesia (autonomic or somatic response), the target concentration was increased by 1 or 2 ng/ml. If no response occurred during a 15-min period, the concentration was decreased by 1 or 2 ng/ml. Remifentanil pharmacodynamics and pharmacokinetics were estimated using NONMEM. Results: The remifentanil blood concentration for which there is a 50% probability of adequate anesthesia during abdominal surgery (Cb50) with 66% nitrous oxide was 4.1 ng/ml in men and 7.5 ng/ml in women. The Cb50 values for prostatectomy, nephrectomy, and other abdominal procedures were 3.8, 5.6, and 7.5 ng/ml, respectively. Remifentanil pharmacokinetics were best described by a two-compartment model with lean body mass as a significant covariate, where V1 = 0.129(lean body mass-50) + 3.79 l, V2 = 6.87 l, CL1 = 0.0389(lean body mass-50) + 2.34 l/min and CL2 = 1.14 l/min. Conclusions: The Cb50 differed according to patient gender. However, because surgery type was not specified for each man or woman, this may reflect a difference in surgical procedure.Keywords
This publication has 13 references indexed in Scilit:
- Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of RemifentanilAnesthesiology, 1997
- Remifentanil Versus AlfentanilAnesthesiology, 1996
- Determination of remifentanil in human and dog blood by HPLC with UV detectionJournal of Pharmaceutical and Biomedical Analysis, 1994
- Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient SurgeryAnesthesiology, 1993
- Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra-Short-Acting OpioidAnesthesia & Analgesia, 1993
- The Pharmacokinetics of the New Short-acting Opioid Remifentanil (GI87084B) in Healthy Adult Male VolunteersAnesthesiology, 1993
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Measuring the predictive performance of computer-controlled infusion pumpsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Pharmacodynamics of Alfentanil The Role of Plasma Protein BindingAnesthesiology, 1992
- Plasma Concentrations of Alfentanil Required to Supplement Nitrous Oxide Anesthesia for General SurgeryAnesthesiology, 1986